InvestorsHub Logo

moonotaur

07/02/20 3:05 AM

#284074 RE: alm2 #284073

If this gets overturned, this is exactly what Amarin needed to solidify its IP going forward and most likely open doors for any potential buyouts.

The IP went through the wringer here and it will have been completely derisked.

So yes it has been awful but the damage has not been irreparable. In fact, given COVID as well, this could all turn out to be the “best” thing that could have happened for a buyout. Gave mgmt an excuse to pump breaks on cash burn while solidifying IP and also bought time waiting for EMA approval.

postes

07/02/20 3:06 AM

#284075 RE: alm2 #284073

Alm...no amicus from any pharma...this litigation is not going to discourage Pharma R&D.